Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Benchmark Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $57

Benchmark Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $57

Benchmark analyst Bruce Jackson initiates coverage on Belite Bio (NASDAQ:BLTE) with a Buy rating and announces Price Target of $57.

July 1, 2022

1 minute read

Benchmark analyst Bruce Jackson initiates coverage on Belite Bio (NASDAQ:BLTE) with a Buy rating and announces Price Target of $57.

Raymond James Maintains Outperform Rating for Old Dominion Freight Line: Here’s What You Need To Know

July 7, 1:00 PM

Raymond James has decided to maintain its Outperform rating of Old Dominion Freight Line (NASDAQ:ODFL) and raise its…

February 13, 8:37 AM

Benchmark analyst Bill Sutherland reiterates Amedisys (NASDAQ:AMED) with a Buy and maintains $120 price target.

November 30, 5:00 PM

Analysts have provided the following ratings for Vestis (NYSE:VSTS) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

November 4, 11:54 AM

Wells Fargo analyst Praneeth Satish maintains Generac Hldgs (NYSE:GNRC) with a Overweight and lowers the price target from $175 to $155.